Literature DB >> 15786430

Cryoablation and cryolocalization in the management of breast disease.

Pat W Whitworth1, John C Rewcastle.   

Abstract

Cryotechnology is currently used for both treatment and diagnosis of breast disease. Due to the natural analgesic effect of cold, cryoablation is potentially more patient-friendly than other technologies which raise tissue temperature. Freezing produces a predictable volume of necrosis and is easily observed and controlled during treatment. Recent studies have demonstrated that, as a primary therapy for breast fibroadenoma, cryoablation is safe and effective with durable results that can be reproduced in community practices. Certain barriers do exist before cryoablation, or any other in situ ablation, can become a standard therapy for the treatment of localized breast malignancy. Investigations are underway to refine patient selection criteria and develop valid confirmatory assays so that clinical trials can begin. Cryolocalization, which creates a well-delineated, palpable mass of frozen tissue encompassing a tumor, is a relatively new application of cold in medicine. This strategy promises to reduce positive margin rates during lumpectomy of non- or barely-palpable tumors. Finally, cryotechnology now also aids in the collection of tissue for histological analysis. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2005        PMID: 15786430     DOI: 10.1002/jso.20201

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  6 in total

1.  Non-surgical treatment of early breast cancer: techniques on the way.

Authors:  Alaa Hamza; Shymaa Elrefaey
Journal:  Gland Surg       Date:  2014-08

2.  Cryoablation Without Excision for Low-Risk Early-Stage Breast Cancer: 3-Year Interim Analysis of Ipsilateral Breast Tumor Recurrence in the ICE3 Trial.

Authors:  Richard E Fine; Richard C Gilmore; Jill R Dietz; Susan K Boolbol; Michael P Berry; Linda K Han; Andrew S Kenler; Michael Sabel; Kenneth R Tomkovich; Noam A VanderWalde; Margaret Chen; Karen S Columbus; Lisa D Curcio; Sheldon M Feldman; Linsey Gold; Lydia Hernandez; Eric R Manahan; Susan A Seedman; Rashmi P Vaidya; Alexander B Sevrukov; Hussein D Aoun; Randy D Hicks; Rache M Simmons
Journal:  Ann Surg Oncol       Date:  2021-08-15       Impact factor: 5.344

Review 3.  Pharmacodynamic endpoints as clinical trial objectives to answer important questions in oncology drug development.

Authors:  Ralph E Parchment; James H Doroshow
Journal:  Semin Oncol       Date:  2016-07-26       Impact factor: 4.929

Review 4.  Cryosurgery for breast fibroadenomas.

Authors:  Lizhi Niu; Binghui Wu; Kecheng Xu
Journal:  Gland Surg       Date:  2012-08

Review 5.  Cryosurgery of breast cancer.

Authors:  Lizhi Niu; Liang Zhou; Kecheng Xu
Journal:  Gland Surg       Date:  2012-08

Review 6.  Clinical application status and prospect of the combined anti-tumor strategy of ablation and immunotherapy.

Authors:  Li Yin; Xing-Yu Li; Lin-Lin Zhu; Gui-Lai Chen; Zhuo Xiang; Qing-Qing Wang; Jing-Wang Bi; Qiang Wang
Journal:  Front Immunol       Date:  2022-09-05       Impact factor: 8.786

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.